Moleculin Biotech, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Moleculin Biotech, Inc.
A new COVID-19 vaccine dream team, updated trial results on remdesivir, and a rough first quarter for big pharma stocks. In addition to our daily in-depth coverage of key regulatory events relating to the coronavirus pandemic, these three topics are among a selection of brief insights we’re bringing you on biopharma commercial activities.
Plus: Moleculin hopes to move 2-DG prodrug into clinic, India progresses niche COVID-19 defenses and more.
Deals involving Hoth/Voltron, Vir/Xencor, Akers/Premas, WPD/CNS address coronavirus outbreak. Separately, Roche and Forge hope to develop a novel antibiotic for Gram-negative infections using the LpxC enzyme.
Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.
- Other Names / Subsidiaries
- Moleculin Australia Pty. Ltd.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.